MYCOVACC
About MYCOVACC
The CCS National Active Surveillance Study of Myocarditis and/or Pericarditis following mRNA COVID-19 Vaccination (MYCOVACC)is a multi-centre, pan-Canadian study of the long-term impact of myocarditis and pericarditis after mRNA COVID-19 vaccination funded by the Public Health Agency of Canada from 2022 to 2026.
Contact the MYCOVACC Study Team
Email: mycovacc@ccs.ca
Clinical Resources
Access podcasts, publications, continuing professional development, and infographics
Listen:
Join Dr. Michael McDonald, member of the MYCOVACC Steering Committee, as he discusses new clinical resources about post-vaccine myocarditis and pericarditis available on the CCS website: www.ccs.ca/mycovacc/.
Read:
McDonald, M.A., Kafil, T.S, Khoury, M., Luk, A.C., Wright, M.K, & Hawkins, N. M. (2024). Myocarditis and pericarditis following mRNA COVID-19 vaccination: 2024 status and management update. Canadian Journal of Cardiology. https://doi.org/10.1016/j.cjca.2024.03.016
Watch:
Myocarditis and Pericarditis after mRNA COVID-19 Vaccination: Status and Management Update (2024)
This CCS continuing professional development webinar provides an update on post-vaccine myocarditis and pericarditis from public health, cardiology, and family medicine perspectives.
Unmasking the Cardiac Legacy of COVID-19: Insights and Impacts in 2025 (2025)
This CCS continuing professional development webinar addresses the acute and chronic cardiovascular effects of COVID-19 infection as well as the benefits and risks associated with mRNA COVID-19 vaccination.
Beyond the Acute Phase: Cardiac MRI Insights from the CCS National Active Surveillance Study of Myocarditis and/or Pericarditis following mRNA COVID-19 Vaccination (2026)
This CCS continuing professional development webinar updates the cardiovascular community on results from the Canadian Cardiovascular Society National Active Surveillance Study of MYocarditis and/or Pericarditis following mRNA COVID-19 VACCination (MYCOVACC) with particular focus on cardiac magnetic resonance imaging (MRI) findings.
Learn:
This CCS online course provides an update on myocarditis and pericarditis after mRNA COVID-19 vaccination from public health, cardiology, and family medicine perspectives. Dr. Anil Gupta chairs the session. Panelists include Dr. Daisy de la Cruz Davalos, Dr. Nat Hawkins, Dr. Tahir Kafil, Dr. Alexander Singer and Dr. Tonja Stothart.
Section 3 Course: Unmasking the Cardiac Legacy of COVID-19: Insights and Impacts in 2025
This on-line course addresses the acute and chronic cardiovascular effects of COVID-19 infection as well as the benefits and risks associated with mRNA COVID-19 vaccination. Dr. Anil Gupta chairs the session. Panelists are Dr. Naveed Janjua, Dr. Thao Huynh, Dr. Satish Raj, and Dr. Nat Hawkins.
Use:
Information for Patients:
Management Algorithm for Health Care Providers:
The updated post-vaccine myocarditis and pericarditis resources were developed in collaboration with the Centre for Evidence-Based Implementation, McMaster University. They are informed by Myocarditis and Pericarditis following mRNA COVID-19 Vaccination: 2024 Status and Management Update in the Canadian Journal of Cardiology. The resources are available in English and French.
News
Read news releases and newsletters
News Releases
Newsletters
Governance
Learn about MYCOVACC committees
The MYCOVACC governance structure aims to facilitate the participation and collaboration of CCS members, CCS Affiliate societies, investigators, and patients in study activities.
Steering Committee
The MYCOVACC Steering Committee provides direction, guidance, and decision-making about study activities. Specifically, the Committee: guides implementation, operations, and funding; and ensures key study deliverables are achieved. The committee is chaired by Dr. Nathaniel Hawkins. It includes CCS members as well as representatives from key partner networks and the Public Health Agency of Canada.
Scientific and Data Management Committee
The MYCOVACC Scientific and Data Management Committee ensures high-quality data, and ethical data collection, storage, and use. The Committee reviews and makes recommendations to the Steering Committee about all protocols, publications, and reports. The Committee is chaired by Dr. James White and includes CCS members as well as experts from across the scientific community with experience in public health, scientific methodology and data management.
Integrated Knowledge Translation Committee
The MYCOVACC Integrated Knowledge Translation (IKT) Committee develops and supports knowledge translation strategies and activities. The IKT Committee ensures MYCOVACC knowledge products meet the needs of the project’s key stakeholder groups. The Committee is chaired by Dr. Michael McDonald and includes CCS members as well as representatives from across the fields of science and medicine with expertise and experience in knowledge translation and communications. The Committee also consults with patient advisors.
Join the MYCOVACC study
Study site and patient recruitment have closed.
The views expressed herein do not necessarily represent the views of the Public Health Agency of Canada.